Sacrosidase
| Names | |
|---|---|
| Trade names | Sucraid |
| Clinical data | |
| Drug class | Enzyme[1] |
| Main uses | Congenital sucrase-isomaltase deficiency (CSID)[2] |
| Side effects | Abdominal pain, nausea, diarrhea, trouble sleeping, headache[2] |
| Routes of use | By mouth |
| Typical dose | 2 ml with food[2] |
| External links | |
| AHFS/Drugs.com | Monograph |
| Legal | |
| Legal status |
|
Sacrosidase, sold under the brand name Sucraid, is a medication used to treat congenital sucrase-isomaltase deficiency (CSID).[2] Use may also help support the diagnosis of the condition in question.[2] It is taken by mouth each time a person eats.[2]
Common side effects include abdominal pain, nausea, diarrhea, trouble sleeping, and headache.[2] Other side effects may include allergic reactions.[2] It replace the enzyme sucrase which assists in the breakdown of sugar (sucrose) into simpler forms.[2]
Sacrosidase was approved for medical use in the United States in 1998.[2] In the United States 118 doses costa about 8,700 USD as of 2021.[3] In Europe it is an orphan medicine.[1]
Medical use
Dosage
It is taken at a dose of 17,000 units (2 ml) in those over 15 kg each time they eat.[2]
Chemistry
Sacrosidase is dispensed as a clear solution, with a pale yellow tint, which has a sweet taste. Users must take with food and patients who take Sucraid can maintain a normal diet. Sucraid is packaged in two plastic bottles, each 118ml. A scoop to measure Sucraid is included within the package.
References
- ↑ 1.0 1.1 "Sacrosidase". SPS - Specialist Pharmacy Service. 31 January 2017. Archived from the original on 9 October 2021. Retrieved 9 October 2021. Archived 9 October 2021 at the Wayback Machine
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 "Sacrosidase Monograph for Professionals". Drugs.com. Archived from the original on 16 July 2017. Retrieved 9 October 2021. Archived 16 July 2017 at the Wayback Machine
- ↑ "Sucraid Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 September 2021. Retrieved 9 October 2021.
External links
| Identifiers: |
|---|
